Cramer says investors shouldn’t fear market declines and instead look for buying opportunities

Cramer says investors shouldn’t fear market declines and instead look for buying opportunities


CNBC’s Jim Cramer on Tuesday said that investors shouldn’t fear the market’s declines now that interest rates are coming down since that means there are buying opportunities.

“You can’t have it both ways. You can’t be scared of higher rates and lower rates. History says we should like lower interest rates. … And, of course, it’s a sign that the Fed is winning its war against inflation after a couple of aggressive rate hikes,” the “Mad Money” host said.

“So should we hate this market or learn to love it? Wrong question. Perhaps, we should like the stocks that now sell at historically, even record-breaking low valuations,” he added.

U.S. stocks concluded a rough end to the first half of the year in June. The benchmark 10-year Treasury yield and the two-year yield inverted on Tuesday — a sign that historically indicates a recession is looming. When short-term Treasury yields are above long-term yields, it suggests that investors believe an economic slowdown will result in interest rate cuts.

Tech stocks rose on Tuesday while stocks associated with economic growth fell. Oil also tumbled, with the U.S. benchmark West Texas Intermediate dropping below $100 a barrel. 

Cramer said that instead of bemoaning the market’s downturn, investors should see it as a buying opportunity.

“We can’t act like there have been no declines. … In fact, with the collapse of the oils, there’s no group left that hasn’t been savaged,” he said. “That may be enough to justify thinking more positively about this entire now-despised asset class, too. Funny thing about stocks — they do still get cheaper as they go lower.”



Source

Moderna says FDA refuses to review its application for experimental flu shot
Business

Moderna says FDA refuses to review its application for experimental flu shot

A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration has refused to start a review of Moderna‘s application for its experimental flu shot, the company announced Tuesday, in another sign of the […]

Read More
Estee Lauder sues Walmart alleging ‘despicable’ sale of counterfeit beauty products
Business

Estee Lauder sues Walmart alleging ‘despicable’ sale of counterfeit beauty products

Walmart Inc. signage during the company’s listing at the Nasdaq MarketSite in New York, US, on Tuesday, Dec. 9, 2025. Michael Nagle | Bloomberg | Getty Images Estee Lauder sued Walmart in California federal court over allegations the big-box retailer sold counterfeit beauty products on its website and didn’t do enough to ensure only authorized […]

Read More
How this French building behemoth wants to solve the U.S. housing dilemma
Business

How this French building behemoth wants to solve the U.S. housing dilemma

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. French […]

Read More